Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone

@article{Harvey2011PerformanceAI,
  title={Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone},
  author={Philip D. Harvey and M. Ogasa and J. Cucchiaro and A. Loebel and R. Keefe},
  journal={Schizophrenia Research},
  year={2011},
  volume={127},
  pages={188-194}
}
BACKGROUND Improving cognitive functioning in people with schizophrenia is a major treatment goal. In addition, interview-based measures have been developed to supplement performance-based assessments. However, few data are available regarding whether interview-based measures are sensitive to treatment-related changes. METHODS Adult outpatients who met DSM-IV criteria for schizophrenia or schizoaffective disorder were randomized to 21 days of double-blind treatment with lurasidone 120 mg once… Expand
Reliability, validity and treatment sensitivity of the Schizophrenia Cognition Rating Scale
Factors influencing self-assessment of cognition and functioning in schizophrenia: Implications for treatment studies
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 36 REFERENCES
Neuropsychological normalization with long-term atypical antipsychotic treatment: results of a six-month randomized, double-blind comparison of ziprasidone vs. olanzapine.
The Cognitive Assessment Interview (CAI): Development and validation of an empirically derived, brief interview-based measure of cognition
A brief cognitive assessment for use with schizophrenia patients in community clinics
Self-assessment of functional status in schizophrenia.
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
...
1
2
3
4
...